GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Cyclically Adjusted PS Ratio

Surmodics (Surmodics) Cyclically Adjusted PS Ratio : 4.27 (As of May. 15, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Surmodics Cyclically Adjusted PS Ratio?

As of today (2024-05-15), Surmodics's current share price is $33.00. Surmodics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $7.72. Surmodics's Cyclically Adjusted PS Ratio for today is 4.27.

The historical rank and industry rank for Surmodics's Cyclically Adjusted PS Ratio or its related term are showing as below:

SRDX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.49   Med: 5.53   Max: 15.92
Current: 4.2

During the past years, Surmodics's highest Cyclically Adjusted PS Ratio was 15.92. The lowest was 2.49. And the median was 5.53.

SRDX's Cyclically Adjusted PS Ratio is ranked worse than
65.4% of 474 companies
in the Medical Devices & Instruments industry
Industry Median: 2.165 vs SRDX: 4.20

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Surmodics's adjusted revenue per share data for the three months ended in Mar. 2024 was $2.253. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.72 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Surmodics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Surmodics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Cyclically Adjusted PS Ratio Chart

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.07 7.31 9.24 4.43 4.24

Surmodics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 4.21 4.24 4.77 3.80

Competitive Comparison of Surmodics's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Surmodics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Surmodics's Cyclically Adjusted PS Ratio falls into.



Surmodics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Surmodics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=33.00/7.72
=4.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Surmodics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.253/129.4194*129.4194
=2.253

Current CPI (Mar. 2024) = 129.4194.

Surmodics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.058 100.560 1.362
201409 1.109 100.428 1.429
201412 1.058 99.070 1.382
201503 1.091 99.621 1.417
201506 1.198 100.684 1.540
201509 1.317 100.392 1.698
201512 1.254 99.792 1.626
201603 1.266 100.470 1.631
201606 1.503 101.688 1.913
201609 1.368 101.861 1.738
201612 1.321 101.863 1.678
201703 1.303 102.862 1.639
201706 1.329 103.349 1.664
201709 1.503 104.136 1.868
201712 1.302 104.011 1.620
201803 1.415 105.290 1.739
201806 1.683 106.317 2.049
201809 1.735 106.507 2.108
201812 1.609 105.998 1.965
201903 1.645 107.251 1.985
201906 1.774 108.070 2.124
201909 2.235 108.329 2.670
201912 1.643 108.420 1.961
202003 1.660 108.902 1.973
202006 1.950 108.767 2.320
202009 1.619 109.815 1.908
202012 1.631 109.897 1.921
202103 2.503 111.754 2.899
202106 1.725 114.631 1.948
202109 1.703 115.734 1.904
202112 1.658 117.630 1.824
202203 1.876 121.301 2.002
202206 1.784 125.017 1.847
202209 1.864 125.227 1.926
202212 1.783 125.222 1.843
202303 1.939 127.348 1.971
202306 3.730 128.729 3.750
202309 1.989 129.860 1.982
202312 2.167 129.419 2.167
202403 2.253 129.419 2.253

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Surmodics  (NAS:SRDX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Surmodics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Surmodics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (Surmodics) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Executives
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344

Surmodics (Surmodics) Headlines

From GuruFocus

Surmodics Receives FDA Approval for the SurVeil� Drug-Coated Balloon

By Business Wire Business Wire 06-20-2023